Correction to: Efficacy of Radiofrequency Ablation in Patients with Metastatic Liver Tumors from Breast Carcinoma

Zahra Mardanshahi1,
Yaghob Sakhaeei2,
Mohammad Khademloo3,
Gahsem Janbabai4,
Seyed Ghader Aghili5,
Maryam Tayebi6

1 Assistant Professor, Department of Radiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2 Assistant Professor, Department of Radiology, Faculty of Medicine, Islamic Azad University, Sari Branch, Mazandaran, Sari, Iran
3 Associate Professor, Department of Community Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4 Associate Professor, Department of Oncology, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
5 Radiologist, Department of Radiology, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
6 MSc in Medical Imaging, Department of Radiology, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

In the article published in Volume 27, issue 158, 2017, the Results section in English Abstract have been published incorrectly. The correct Results is given below:

Results: The most frequent sizes of mass were 2-4 cm (n=33, 54%) and 4-5 cm (n=23, 38%). Among the patients, 35 (67.3%) had one tumor before, in 11.5% renew tumor happened, and 65.4% had one tumor after treatment. Liver tumors were controlled in 76.9% in case group which was statistically higher than that in control group (P< 0.0001).
اصلاحی: بررسی تأثیر درمانی اسپارانج رادیو فرکونسی در بیماران با تومورهای متاستاتیک کبد با منشا، پستان

رضا مردانشاهی، عباسی سخاپور، محمد خادملو، قاسم جان بابایی، سید قادر عقیلی، مريم طبیعی

ارائه شده: مجله دانشگاه علوم پزشکی مازندران
دوره 28، شماره 261، تیر 1391

Result در مقاله فوق که در شماره 158 اسفند 1396 در دوره 27 این تشریح شده بود، قسمت است

Results: The most frequent sizes of mass were 2-4 cm (n=33, 54%) and 4-5 cm (n=23, 38%).
Among the patients, 35 (67.3%) had one tumor before, in 11.5% renew tumor happened, and 65.4% had one tumor after treatment. Liver tumors were controlled in 76.9% in case group which was statistically higher than that in control group (P< 0.0001).